Document:

Amendment No. 1 to the Assignment and License Agreement

 EXHIBIT 10.2 
  
 AMENDMENT NO. 1 
 TO 

ASSIGNMENT AND LICENSE AGREEMENT 
  
 This Amendment No. 1 to Assignment and License Agreement (this “Agreement”) is dated as of November 2, 2004 and is made by and among
Chromodynamics, Inc., a Pennsylvania corporation (“CDI”), Spectral Molecular Imaging, Inc., a Nevada corporation formerly named Spectral Molecular Technologies, Inc. (“Spectral”), and Daniel L. Farkas, Miriam Farkas, Elliot
Wachman and Jill Wachman (these four individuals, collectively, the “Inventors”). 
  
 RECITALS 
  
 WHEREAS, CDI,
Spectral and the Inventors (collectively, the “Parties”) previously entered into an Assignment and License Agreement, dated as of November 1, 2004 (the “Assignment Agreement”); and 
  
 WHEREAS, the Parties wish to amend certain provisions of the Assignment
Agreement. 
  
 NOW, THEREFORE, the Parties agree as follows:

  
 1. Section 4.1 Amendment. Section 4.1 of the
Assignment Agreement is hereby amended by changing the reference therein to thirty (30) days from the date of the Assignment Agreement to fifty (50) days from the date of the Assignment Agreement. 
  
 2. Section 4.4 Amendment. Section 4.4(a) of the Assignment
Agreement is hereby amended by adding a fourth and fifth sentence to that Section, which sentences shall read in full as follows: 
  
 “In the event Spectral is required to pay a royalty or other similar payment to CMU or any third party in order to make, use or sell
Endoscopic Products without violating the intellectual property rights of that party, the foregoing royalty payable by Spectral to the Inventors that is based on Net Sales of Endoscopic Products shall be reduced by the amounts, if any, that are
payable to each of such third parties (before similar offsets under the third party agreement); provided, however, that in no event will the royalty payable to the Inventors due to this offset be reduced below {***}. In the event Spectral is
required to pay a royalty or other similar payment to any third party (other than CMU) in order to make, use or sell CMU Products without violating the intellectual property rights of that party, the foregoing royalty payable by Spectral to CDI that
is based on Net Sales of CMU Products shall be reduced by the amounts, if any, that are payable to each of such third parties (before similar offsets under the third party agreement); provided, however, that in no event will the royalty payable to
CDI (after first taking into account any required payment by Spectral to CMU) be reduced by more than {***}. 
  
 Portions marked with {***} have been omitted pursuant to a Request for Confidential Treatment and were filed separately with the Commission. 

 3. Miscellaneous. This Agreement, together with the Assignment Agreement as modified by this
Agreement, constitutes the entire agreement of the Parties pertaining to the subject matter of this Agreement. This Agreement may be executed in one or more counterparts, each of which is an original and all of which together constitute one and the
same instrument. 
  
 IN WITNESS WHEREOF, the parties have caused
this Agreement to be executed by their duly authorized representatives as of the day and year first indicated above. 
  

					
	 CHROMODYNAMICS, INC.

		
	By: 	 	 /s/ Jill Wachman

	 	 	 Name: 
	 	 Jill Wachman, M.D.

	 	 	 Title: 
	 	 Vice President

	
	 SPECTRAL MOLECULAR IMAGING, INC.

		
	By: 	 	 /s/ Manfred Mosk

	 	 	 Name: 
	 	 Dr. Manfred Mosk

	 	 	 Title: 
	 	 Interim Chief Executive Officer

  

	
	
	 /s/ Daniel L. Farkas

	 DANIEL L. FARKAS

	
	 /s/ Miriam Farkas

	 MIRIAM FARKAS

	
	 /s/ Elliot Wachman

	 ELLIOTT WACHMAN

	
	 /s/ Jill Wachman

	 JILL WACHMAN

  

 2Amendment No. 2 to the Assignment and License Agreement

 EXHIBIT 10.3 
  
 AMENDMENT NO. 2 
 TO 

ASSIGNMENT AND LICENSE AGREEMENT 
  
 This Amendment No. 2 to Assignment and License Agreement (this “Agreement”) is dated as of October 20, 2005 and is made by and among
ChromoDynamics, Inc., a Pennsylvania corporation (“CDI”), Spectral Molecular Imaging, Inc., a Nevada corporation formerly named Spectral Molecular Technologies, Inc. (“Spectral”), and Daniel L. Farkas, Miriam Farkas, Elliot
Wachman and Jill Wachman (these four individuals, collectively, the “Inventors”). 
  
 RECITALS 
  
 WHEREAS, CDI,
Spectral and the Inventors (collectively, the “Parties”) previously entered into an Assignment and License Agreement, dated as of November 1, 2004, as amended by Amendment No. 1, dated as of November 2, 2004 (collectively,
the “Assignment Agreement”); 
  
 WHEREAS, the Parties
wish to amend certain provisions of the Assignment Agreement. 
  
 NOW, THEREFORE, the Parties agree as follows: 
  
 1.
Amendment to Section 2.2. Section 2.2 of the Assignment Agreement is hereby amended to read in full as follows: 
  
 “Section 2.2. CMU Technology. CDI and the Inventors shall use their commercially reasonable best efforts to assist Spectral,
at Spectral’s cost and expense, in acquiring a direct, exclusive, worldwide license from CMU of the CMU Technology for use in developing (including pre-clinical development work) and commercializing the Endoscopic Invention and otherwise for
use in developing (including pre-clinical development work) and commercializing dermoscopic applications and devices and other in vivo imaging applications and devices for ultimate clinical use (collectively, the “Endoscopic
Applications”). CDI and the Inventors hereby consent to Spectral entering into a direct license with CMU for the CMU Technology pursuant to a license agreement between CMU and Spectral having terms in accordance with the license agreement
attached hereto as Exhibit C. If Spectral is unable to obtain a direct, exclusive, worldwide license from CMU of the CMU Technology on or before December 31, 2005, then CDI shall, subject to the terms of this Agreement, grant as of that date to
Spectral an exclusive, worldwide sublicense to develop, manufacture, market, distribute, import, offer for sale and sell CMU Products, both on its own and through one or more Affiliates, distributors and sublicenses, for the Endoscopic Applications;
provided, however, that the sublicense to the CMU Technology, if granted by CDI to Spectral pursuant to this Section 2.2, will terminate immediately upon the termination of the CMU License Agreement. Upon 
  
 Portions marked with {***} have been omitted pursuant to a Request for Confidential Treatment
and were filed separately with the Commission. 

 any sublicense to Spectral under this Section 2.2, Spectral shall assume, along with CDI, all of
CDI’s obligations under the CMU License Agreement. CDI shall use its commercially reasonable best efforts to maintain the CMU License Agreement in full force and effect and shall promptly notify Spectral in writing of any prospective or actual
default hereunder by CDI. CDI shall also use its commercially reasonable best efforts to obtain CMU’s agreement to enter into a direct license with Spectral having the same terms and conditions as the CMU License Agreement in the event that
agreement is terminated by CMU due to a default by CDI. Spectral may sublicense the rights granted in this Section 2.2; provided, however, that Spectral shall obtain CDI’s prior written consent, which consent shall not be unreasonably
withheld or delayed, in the case of any sublicense to an entity other than an Affiliate of Spectral.” 
  
 2. Amendment to Section 4.4. Section 4.4(a) of the Assignment Agreement is hereby amended to read in full as follows: 
  
 “(a) Spectral shall pay to the Inventors an amount
equal to {***}, but in the case of Net Sales of Endoscopic Products by SMI’s licensees not more than an amount equal to {***}. Spectral shall, in the case of a direct license with CMU, pay a total of {***}, with CDI to receive {***}. Spectral
shall, in the case of a sublicense from CDI, pay CDI {***}. In the event Spectral is required to pay a royalty or other similar payment to CMU or any third party in order to make, use or sell Endoscopic Products without violating the intellectual
property rights of that party, the foregoing royalty payable by Spectral to the Inventors that is based on Net Sales of Endoscopic Products shall be reduced by the amounts, if any, that are payable to each of such third parties (before similar
offsets under the third party agreement); provided, however, that in no event will the royalty payable to the Inventors due to this offset be reduced by more than {***}. In the event Spectral is required to pay a royalty or other similar payment to
any third party (other than CMU) in order to make, use or sell CMU Products without violating the intellectual property rights of that party, the foregoing royalty payable by Spectral to CDI that is based on Net Sales of CMU Products shall be
reduced by the amounts, if any, that are payable to each of such third parties (before similar offsets under the third party agreement); provided, however, that in no event will the royalty payable to CDI (after first taking into account any
required payment by Spectral to CMU) be reduced by more than {***}.” 
  

 2 

 3. Amendment to Section 10.1. Section 10.1 of the Assignment Agreement is hereby amended
to read in full as follows: 
  
 “Section
10.1. Notices 
  

	 	(a)	Every notice or other communication required or contemplated by this Agreement must be in writing and sent by one of the following methods: 

  

	 	(i)	personal delivery, in which case delivery will be deemed to occur the day of delivery; 

  

	 	(ii)	certified or registered mail, postage prepaid, return receipt requested, in which case delivery will be deemed to occur the day it is officially recorded by the U.S. Postal Service
as delivered to the intended recipient; or 

  

	 	(iii)	next-day delivery to a U.S. address by recognized overnight delivery service such as FedEx, in which case delivery will be deemed to occur upon receipt. 

  

	 	(b)	In each case, a notice or other communication sent to a party must be directed to the address for that party set forth below, or to another address designated by that party by
written notice: 

  
 If to CDI, to:

  
 ChromoDynamics, Inc. 
 1195 Airport Road, Unit #1 
 Lakewood, New
Jersey 08701 
 Attention: Elliot Wachman 
 Fax: 732-730-1879 
  
 If to
Spectral, to: 
  
 Spectral Molecular Imaging, Inc.

 8797 Beverly Boulevard 
 Suite 310 
 Los Angeles, California 90048 
 Attention: David Wohlberg 
 Fax: 310-201-4746 
  
 If to Daniel L. Farkas, to: 
  
 Daniel L. Farkas 
 8591 Skyline Drive 
 Los Angeles, California 90046 
  

 3 

 If to Miriam Farkas, to: 
  
 Miriam Farkas 
 8591 Skyline Drive 
 Los Angeles, California 90046 
  
 If to Elliott Wachman, to: 
  

Elliot Wachman 
 620 8th Street 
 Lakewood, New Jersey 08701 
  
 If to Jill Wachman,
to: 
  
 Jill Wachman 
 620 8th Street

 Lakewood, New Jersey 08701” 
  
 4. Miscellaneous. This Agreement, together with the Assignment Agreement as modified by this Agreement, constitutes the entire agreement of the
Parties pertaining to the subject matter of this Agreement. This Agreement may be executed in one or more counterparts, each of which is an original and all of which together constitute one and the same instrument. 
  
 (remainder of this page intentionally blank) 
  

 4 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the day and year first indicated above. 
  

					
	 CHROMODYNAMICS, INC.

		
	 By: 
	 	 /s/ Jill Wachman

	 	 	 Name: 
	 	 Jill Wachman, M.D.

	 	 	 Title: 
	 	 Vice President

	
	 SPECTRAL MOLECULAR IMAGING, INC.

		
	 By: 
	 	 /s/ David Wohlberg

	 	 	 Name: 
	 	 David J. Wohlberg

	 	 	 Title: 
	 	 President

  

	
	
	 /s/ Daniel L. Farkas

	 DANIEL L. FARKAS

	
	 /s/ Miriam Farkas

	 MIRIAM FARKAS

	
	 /s/ Elliot Wachman

	 ELLIOT WACHMAN

	
	 /s/ Jill Wachman

	 JILL WACHMAN

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]